Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesHistone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
Oncogene, 10/08/09
Borbone E et al. – The combined treatment with HDAC and proteasome inhibitors results in synergistic apoptosis. These results strongly encourage the preclinical application of the combination deacetylase–proteasome inhibitors for the treatment of ATC.
Related Articles
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors
British Journal of Haematology, 10/05/09
Relevance Score: 81%
Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells
American Journal of Physiology: Renal Physiology, 11/12/09
Relevance Score: 80%
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Cancer Science, 10/26/09
Relevance Score: 80%
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
Journal of Clinical Oncology, 10/20/09
Relevance Score: 80%
Histone Deacetylase Inhibitors in Cancer Therapy
Journal of Clinical Oncology, 10/16/09
Relevance Score: 80%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Haematologica, 12/20/09
The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation
Journal of Thrombosis and Haemostasis, 12/20/09
Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors
Cancer Research, 12/20/09
Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters
Experimental and Clinical Endocrinology & Diabetes, 12/19/09
Diagnostic Accuracy of rhTSH Test with Neck Ultrasonography in Differentiated Thyroid Cancer Follow-up
Experimental and Clinical Endocrinology & Diabetes, 12/19/09
Thyroid follicular neoplasm: Analysis by fine needle aspiration cytology, frozen section, and histopathology
Diagnostic Cytopathology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor